News
Nordic Nanovector ASA: Increase of Share Capital/Mandatory...
www.informazione.it
The Board of Directors of the Company has, to fulfil the Company's obligations under the RSU agreements, resolved to issue 13,259 new shares at a…
Abraxane & gemcitabine can improve survival in metastatic pc
pancreaticcanceraction.org
“We are excited by the results of the nab-paclitaxel MPACT study and the potential this treatment combination may bring to patients with advanced pancreatic cancer,” said Jean-Pierre Bizzari, Executive Vice President, Hematology & Oncology, Celgene Corporation. “As the largest phase III real-world ...
Celgene Announces Results of Two Studies Evaluating Combo of...
www.benzinga.com
... potential of these novel combinations in patients in subtypes with a poor prognosis,” said Jean-Pierre Bizzari, M.D., Executive Vice President, ...
Azacitidine benefits patients with myelodysplastic syndromes - ecancer
ecancer.org
... study published in The Lancet Oncology earlier this year,” said Jean-Pierre Bizzari, Group Head of Global Oncology/Hematology of Celgene.
sortiert nach Relevanz / Datum